FDA adcomm votes unanimously against Reata's potential Alport syndrome treatment

The US FDA’s Cardiovascular and Renal Drugs Advisory Committee on Wednesday voted 13-0 that the agency should not approve Reata Pharmaceuticals’ bardoxolone methyl capsules as a treatment to slow the progression of chronic kidney disease in those with the rare Alport syndrome.